INTRODUCTION: Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC). METHODS: This phase II single-arm trial assessed the safety and efficacy of first-line lapatinib in combination with paclitaxel in previously untreated patients with HER2-overexpressing MBC. The primary endpoint was the overall response rate (ORR). Secondary endpoints were the duration of response (DoR), time to response, time to progression, progression-free survival (PFS), overall survival, and the incidence and severity of adverse events. All endpoints were investigator- and independent review committee (IRC)-assessed. RESULTS: The IRC-assessed ORR was 51% (29/57 patients with complete or partial response) while the investigator-assessed ORR was 77% (44/57). As per the IRC, the median DoR was 39.7 weeks, and the median PFS was 47.9 weeks. The most common toxicities were diarrhea (56%), neutropenia (44%), rash (40%), fatigue (25%), and peripheral sensory neuropathy (25%). CONCLUSIONS: First-line lapatinib plus paclitaxel for HER2-overexpressing MBC produced an encouraging ORR with manageable toxicities. This combination may be useful in first-line treatment for patients with HER2-overexpressing MBC and supports the ongoing evaluation of this combination as first-line therapy in HER2-overexpressing MBC.
INTRODUCTION:Lapatinib, an orally active tyrosine kinase inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and ErbB2 (HER2), has activity as monotherapy and in combination with chemotherapy in HER2-overexpressing metastatic breast cancer (MBC). METHODS: This phase II single-arm trial assessed the safety and efficacy of first-line lapatinib in combination with paclitaxel in previously untreated patients with HER2-overexpressing MBC. The primary endpoint was the overall response rate (ORR). Secondary endpoints were the duration of response (DoR), time to response, time to progression, progression-free survival (PFS), overall survival, and the incidence and severity of adverse events. All endpoints were investigator- and independent review committee (IRC)-assessed. RESULTS: The IRC-assessed ORR was 51% (29/57 patients with complete or partial response) while the investigator-assessed ORR was 77% (44/57). As per the IRC, the median DoR was 39.7 weeks, and the median PFS was 47.9 weeks. The most common toxicities were diarrhea (56%), neutropenia (44%), rash (40%), fatigue (25%), and peripheral sensory neuropathy (25%). CONCLUSIONS: First-line lapatinib plus paclitaxel for HER2-overexpressing MBC produced an encouraging ORR with manageable toxicities. This combination may be useful in first-line treatment for patients with HER2-overexpressing MBC and supports the ongoing evaluation of this combination as first-line therapy in HER2-overexpressing MBC.
Authors: Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Date: 2014-05-14 Impact factor: 3.641
Authors: Francisco J Esteva; Sandra X Franco; Maura K Hagan; Abenaa M Brewster; Robert A Somer; Will Williams; Allison M Florance; Simon Turner; Steven Stein; Alejandra Perez Journal: Oncologist Date: 2013-05-22
Authors: Neil M Iyengar; Monica N Fornier; Steven M Sugarman; Maria Theodoulou; Tiffany A Troso-Sandoval; Gabriella M D'Andrea; Pamela R Drullinsky; Devika Gajria; Shari B Goldfarb; Elizabeth A Comen; Diana E Lake; Shanu Modi; Tiffany A Traina; Mario E Lacouture; Melanie F Chen; Sujata Patil; José Baselga; Larry Norton; Clifford A Hudis; Chau T Dang Journal: Clin Breast Cancer Date: 2015-09-25 Impact factor: 3.225
Authors: Michelle D Hackshaw; Heather E Danysh; Jasmeet Singh; Mary E Ritchey; Amy Ladner; Corina Taitt; D Ross Camidge; Hiroji Iwata; Charles A Powell Journal: Breast Cancer Res Treat Date: 2020-06-26 Impact factor: 4.872
Authors: Denise A Yardley; Lowell Hart; Linda Bosserman; Mansoor N Salleh; David M Waterhouse; Maura K Hagan; Paul Richards; Michelle L DeSilvio; Janine M Mahoney; Yasir Nagarwala Journal: Breast Cancer Res Treat Date: 2012-12-08 Impact factor: 4.872